For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

89bio, Inc.

USPTO Granted Patents = 16

CIPO Patents = 3

EPO Patents = 3

Forward Citations = 31

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Robert L Hudkins (8 out of 72 patents)

Craig A Zificsak (8 out of 22 patents)

Bruce D Dorsey (6 out of 54 patents)

4. Nadine C Becknell (6 out of 20 patents)

5. Reddeppa Reddy Dandu (6 out of 16 patents)

6. Linda Weinberg (6 out of 11 patents)

7. Allison L Zulli (6 out of 29 patents)

8. Dimitar B Gotchev (6 out of 20 patents)

9. Boris Schwartsburd (3 out of 5 patents)

10. Shaji Joseph (3 out of 3 patents)

11. Melody McWherter (2 out of 9 patents)

12. David B Whitman (2 out of 9 patents)

13. Hank Mansbach (2 out of 2 patents)

14. Chih-Ming Tseng (2 out of 2 patents)

15. Shawn DeFrees (1 out of 61 patents)

16 patents: Sort by Forward Citations

1. 12350314 - Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates (2025-07-08),

2. 12098130 - 1,4-substituted piperidine derivatives (2024-09-24),

3. 12037376 - Methods of treatment using mutant FGF-21 peptide conjugates (2024-07-16),

4. 12036284 - Compositions and methods of treatment for severe hypertriglyceridemia (2024-07-16),

5. 11878982 - Spiropiperidine derivatives (2024-01-23),

6. 11878966 - Substituted 4-benzyl and 4-benzoyl piperidine derivates (2024-01-23),

7. 11850275 - Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates (2023-12-26),

8. 11702388 - 1,4-substituted piperidine derivatives (2023-07-18),

9. 11596669 - Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates (2023-03-07),

10. 11427623 - Methods of treatment using mutant FGF-21 peptide conjugates (2022-08-30),

11. 11046707 - Spiropiperidine derivatives (2021-06-29),

12. 10919875 - Substituted 4-benzyl and 4-benzoyl piperidine derivatives (2021-02-16),

13. 10874714 - Method of treating fibroblast growth factor 21 (FGF-21) deficiency (2020-12-29),

14. 10851057 - 1,4-substituted piperidine derivatives (2020-12-01),

15. 10407479 - Mutant FGF-21 peptide pegylated conjugates and uses thereof (2019-09-10),

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of non-alcoholic steatohepatitis (NASH). 89bio aims to address unmet medical needs and improve the lives of patients through its novel therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

16 Patents

#292 in San Francisco, CA

#4,631 in California

#19,312 in US

#36,684 in the World

San Francisco, CA, United States of America

89bio, Inc.

Forward Citations = 31

19 inventors:

Robert L Hudkins (8 out of 72 patents)

Craig A Zificsak (8 out of 22 patents)

Bruce D Dorsey (6 out of 54 patents)

4. Nadine C Becknell (6 out of 20 patents)

5. Reddeppa Reddy Dandu (6 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…